Diacerein, identified by its CAS number 13739-02-1, is a pivotal pharmaceutical intermediate that holds significant importance in the development of treatments for inflammatory joint conditions, most notably osteoarthritis. Its chemical structure and pharmacological properties make it a sought-after API for pharmaceutical manufacturers globally. Understanding the intricacies of Diacerein, from its production to its therapeutic applications, is essential for industry professionals.

The chemical identity of Diacerein, also known as diacetylrhein, is C19H12O8. It functions as a slow-acting drug, meaning its effects are not immediate but rather develop over time with consistent use. This characteristic is crucial for its role in managing chronic conditions like osteoarthritis, where sustained reduction in inflammation and protection of joint cartilage are key objectives. The manufacturing process for Diacerein, often carried out in China by specialized chemical companies, focuses on achieving high purity levels to meet pharmaceutical standards.

NINGBO INNO PHARMCHEM CO.,LTD. is a prominent supplier of Diacerein API, offering the raw powder form essential for various pharmaceutical formulations. The company's commitment to quality ensures that the Diacerein provided meets stringent purity requirements, often exceeding 99%. This focus on quality is critical because Diacerein works by inhibiting interleukin-1 beta (IL-1β), a key pro-inflammatory molecule involved in joint tissue destruction. High purity ensures the targeted efficacy of this mechanism.

When sourcing Diacerein, pharmaceutical buyers often look for reliable manufacturers who can guarantee consistent supply and adherence to quality regulations. The competitive landscape of pharmaceutical intermediate suppliers in China provides numerous options, but diligence in selecting a trusted partner is crucial. Information regarding Diacerein price and availability can be obtained by directly contacting manufacturers or through industry platforms that list suppliers of APIs and intermediates.

In summary, Diacerein CAS 13739-02-1 represents a vital component in the pharmaceutical industry, particularly for treatments targeting osteoarthritis. Its unique mechanism of action, coupled with the availability of high-purity raw material from manufacturers in China, solidifies its position as a key pharmaceutical intermediate. Continued research and development utilizing this API promise further advancements in managing inflammatory joint diseases.